BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
BioCentury | Nov 9, 2015
Company News

Mimetogen, Allergan deal

...Mimetogen granted Allergan exclusive, worldwide rights to develop and commercialize tavilermide ( MIM-D3 ) to treat...
BioCentury | Nov 5, 2015
Company News

Allergan strikes dry eye deal with Mimetogen

...Allergan plc (NYSE:AGN) reported 3Q15 earnings and licensed dry eye candidate tavilermide ( MIM-D3 ) from...
...disclosed last week (see BioCentury Extra, Oct. 29) . Allergan will acquire exclusive rights to tavilermide...
...unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) had held an exclusive option to license tavilermide...
BioCentury | Sep 15, 2014
Clinical News

MIM-D3: Phase III data

...Phase III MIM-725 trial in 403 patients with dry eye syndrome showed that twice-daily 1% MIM-D3...
...are corneal fluorescein staining and ocular dryness. Mimetogen did not report data on the latter. MIM-D3...
...8 vs. placebo, including mean blurred vision (p=0.0393), reading (p=0.0433) and watching TV scores (p=0.0046). MIM-D3...
BioCentury | Sep 12, 2014
Clinical News

Bausch + Lomb option to MIM-D3 terminated

...of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to take worldwide rights to dry eye candidate MIM-D3...
...mimetic of nerve growth factor (NGF) . Mimetogen reported the first Phase III data for MIM-D3...
BioCentury | Sep 11, 2014
Clinical News

First Phase III data for Mimetogen's dry eye compound

...Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) reported top-line data from a Phase III trial of MIM-D3 for...
...twice-daily 1% MIM-D3 significantly improved central corneal fluorescein staining vs. placebo at week 8 (p=0.0134). MIM-D3...
...TSX:VRX; NYSE:VRX) obtained an exclusive option to license exclusive, worldwide rights to develop and commercialize MIM-D3...
BioCentury | Jul 22, 2013
Company News

Bausch + Lomb, Mimetogen deal

...Bausch + Lomb an exclusive option to license exclusive, worldwide rights to develop and commercialize MIM-D3...
BioCentury | Oct 4, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Myeloid leukemia cell differentiation protein (MCL1) In vitro studies identified a small molecule MCL1 inhibitor that could help treat leukemia. A competitive screen identified...
BioCentury | Jan 2, 2012
Emerging Company Profile

Anabasis: Eyeing NGF

...is targeting the NGF pathway to treat ophthalmic disease. Mimetogen Pharmaceuticals Inc . is developing MIM-D3...
...June, Mimetogen reported top-line data from a Phase II trial in 150 subjects showing that MIM-D3...
Items per page:
1 - 10 of 28